Jeffrey Casberg, vice president of pharmacy at IPD Analytics, discusses the Alvotech/AbbVie settlement for an adalimumab biosimilar and whether it will impact future patent lawsuits.
Jeffrey Casberg, vice president of pharmacy at IPD Analytics, discusses the Alvotech/AbbVie settlement for an adalimumab biosimilar referencing Humira and whether it will impact future patent lawsuits at the Academy of Managed Care Pharmacy (AMCP) annual meeting.
Transcript:
What do you think that the recent settlement between Alvotech and AbbVie could have for future patent lawsuits, especially for those that may involve the ITC [International Trade Commission]?
Casberg: First, what is the settlement agreement? So, [several] weeks ago, we had a settlement agreement between Alvotech and and AbbVie. Alvotech has a [adalimumab] biosimilar product they're looking to bring to market. AbbVie's the [reference] manufacturer and they'd prefer not to have more competition. But what happened is that both sides had their arguments, but both sides weren't completely sure they would win. And if they did have to go to litigation, the litigation could go on forever, and it could get very expensive.
So, for various reasons, both sides come to a meeting and they say, "Okay, we want this," and they negotiate. They come to a settlement agreement to say, "Okay, we agree that you can launch the biosimilar product, or generic in some cases, on this date." So, that occurred. And the agreement said that alphatech can launch AVT02, the new formulation [referencing] Humira in July 2023.
That changed everything as well, because there was a couple other companies out there, Celltrion Healthcare and Samsung Bioepis/Organon have products. And we hadn't heard much about them. And because we hadn't heard a lot about them, we had figured they probably also had settlement agreements, but weren't saying. So, the information was not publicly available. Now, IPD [Analytics] is assuming that if Alvotech has a settlement agreement with this date, it's likely that Celltrion and Samsung Bioepis/Organon have similar dates.
The settlement agreement is significant because payers can now negotiate with biosimilar manufacturers for both access to original formulation and new formulation products and not have to worry about the conversion effort that would have taken place if only the original formulation came out. So, it changed the game. It's going to make it a lot smoother for payers and a lot better for consumers of the product. It likely will increase adoption of these biosimilar. I think previous to a few weeks ago, adoption would have been modest year 1 [after launch]. I think it will be significantly more than modest now, especially in the second half of the year.
In 2023, we're going to get also interchangeable products. So, for the original formulation we're going to get Cyltezo by Boehringer Ingelheim and Abrilada by Pfizer both launching around July 1 with interchangeability. And then also around July 1, we'll may get the Alvotech/Teva Pharmaceuticals product AVT02 launching with interchangeability. How important is that interchangeability? I guess that's a whole nother session to talk about. So, we'll take that as it comes as [we see] additional launches in 2024 and later.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: Aflibercept Legal Drama; PBM, Humira Biosimilars; Denosumab Regulatory Review
October 15th 2024Regeneron appeals legal decision after judge refuses to block an aflibercept biosimilar; Prime Therapeutics, a pharmacy benefit manager (PBM), becomes the latest to offer biosimilars referencing Humira (adalimumab) at a low cost; the FDA and European Medicines Agency accept a denosumab biosimilar candidate for review.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Pharmacokinetic Modeling Proposes Cost-Effective Dosing for Adalimumab, Etanercept Biosimilars
October 12th 2024A UK cohort study used drug concentration samples from rheumatoid arthritis patients starting the adalimumab biosimilar Amgevita and the etanercept biosimilar Benepali to simulate drug levels under standard and alternate dosing schedules, suggesting that personalized dosing could reduce costs while potentially increasing efficacy.
Samsung Bioepis Report Showcases Adalimumab Biosimilar Growth in Market Share
October 11th 2024Adalimumab biosimilars have seen a significant increase in market share, from 2% in early 2024 to 22%, as payers and pharmacy benefit managers begin to prioritize these biosimilars over the reference product, Humira.